CareONE Concierge Now Accepting Candidates for Alzheimer's Device Study
ATLANTA, July 10, 2025 /PRNewswire/ — CareONE Concierge has announced the launch of a new research study to evaluate an innovative wearable device aimed at addressing cognitive symptoms associated with Alzheimer's-related dementia. The study will utilize NeuroEM Therapeutics'® TEMT-RF cap, a non-invasive device that has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA).
Alzheimer's disease is a growing global health crisis, affecting nearly 7 million Americans and is projected to impact nearly 13 million by 2050. Despite decades of research, treatment options remain limited, with most current therapies only addressing symptoms rather than the underlying causes of cognitive decline. NeuroEM Therapeutics is pioneering Transcranial Electromagnetic Treatment using Radio Frequencies (TEMT-RF) as a potentially groundbreaking approach to treating the disease at its root.
The lightweight, wearable device delivers electromagnetic waves similar to those produced by cell phone signals from multiple emitters. It is being investigated for its potential to break apart toxic protein oligomers within neurons throughout the brain. These oligomers—clusters of beta-amyloid and tau proteins—are thought to drive the progression of Alzheimer's disease. By disrupting these harmful accumulations, TEMT-RF may help restore neuronal function and slow cognitive decline.
'We all know friends and family members who have been impacted by Alzheimer's or dementia,' said Peter Bechtel, CEO of CareONE Concierge. 'This study represents a potential turning point in the fight against these devastating conditions. By participating in this study, individuals have the opportunity to experience cutting-edge, non-drug therapy while contributing to groundbreaking advancements in Alzheimer's treatment.'
This study is independently conducted by CareONE Concierge and is designed for individuals with mild to moderate Alzheimer's-related dementia. Participants will be required to wear the device twice daily for one hour, follow a structured research protocol, and complete cognitive assessments throughout the study.
Dr. Edward Goodwin, Chief Scientist at NeuroEM, emphasized the scientific foundation behind TEMT-RF, stating, 'Our research has shown that TEMT-RF has the potential to impact the key biological processes associated with Alzheimer's disease. This study will help us gather more real-world data on how the device affects cognitive function and overall brain health.'
'NeuroEM is excited to partner with CareONE Concierge,' stated Chuck Papageorgiou, CEO of NeuroEM Therapeutics. 'Our objective is to promote safe, effective, and non-invasive technologies for cognitive health, and research initiatives like this are essential in helping us uncover the full potential of TEMT-RF. With Alzheimer's cases increasing, innovative research such as this provides new hope for patients, caregivers, and the future of cognitive health. Together, we can take meaningful steps toward a future where memory loss is no longer an inevitable part of aging.'
CareONE Concierge is now accepting qualified participants for the study. For more information or to apply, please email CT@careone-concierge.com or apply at www.BestMindForMe.com.
About CareONE ConciergeCareONE Concierge is committed to delivering Preventative Healthcare solutions that meet the needs of patients, providers, and the healthcare system. The company works with physicians, patients, and healthcare systems to develop turnkey solutions that increase patient outcomes while enhancing revenue and quality metrics. To learn more, visit www.careone-concierge.com .
About NeuroEM Therapeutics®NeuroEM Therapeutics is leading the way in the development and clinical testing of bioengineered technology to reverse the cognitive decline associated with Alzheimer's disease and other neurodegenerative conditions. Built upon a decade of groundbreaking research conducted at Tampa-based research facilities at the University of South Florida (USF), the company received the first Breakthrough Device status from the U.S. Food and Drug Administration (FDA) to treat Alzheimer's disease. NeuroEM's continued dedication to cutting-edge research is bringing to market a first-in-class wearable device designed for in-home use to extend healthy longevity using patented Transcranial Electromagnetic Treatment leveraging Radio Frequencies (TEMT-RF) technology. To learn more, visit neuroem.com.
Media Contact:Wendy Stevens, Study Manager(919) 600-9930wstevens@careone-concierge.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
18 hours ago
- Malaysian Reserve
Alpha-synuclein Inhibitors Market to Witness Strong CAGR Through 2034, Driven by Advances in Neurodegenerative Therapies
No alpha-synuclein inhibitors are approved, underscoring a major need for therapies that slow or halt Parkinson's progression. Developing safe, brain-penetrant drugs that target toxic alpha-synuclein while preserving normal function is vital for early intervention and better outcomes. Late-stage candidates like Buntanetap (Annovis Biopharm), Prasinezumab (Roche/Prothena), and Amlenetug (Lundbeck) highlight growing innovation and competition in the alpha-synuclein inhibitors market. LAS VEGAS, July 28, 2025 /PRNewswire/ — DelveInsight's Alpha-synuclein Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Parkinson's disease, Alzheimer's disease, Lewy body dementia, Multiple system atrophy, and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging alpha-synuclein inhibitors, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM. Key Takeaways from the Alpha-synuclein Inhibitors Market Report As per DelveInsight's analysis, the total market size of alpha-synuclein inhibitors in the 7MM is expected to surge significantly by 2034. The report provides the total potential number of patients in the indications, such as Parkinson's disease, Alzheimer's disease, Lewy body dementia, Multiple system atrophy, and others. Leading alpha-synuclein inhibitors companies, such as Annovis Biopharm, Lundbeck, Roche, Prothena, and others, are developing novel alpha-synuclein inhibitors that can be available in the alpha-synuclein inhibitors market in the coming years. Some of the key alpha-synuclein inhibitors in the pipeline include Buntanetap, Amlenetug, Prasinezumab, and others. In March 2025, Annovis Bio participated in AD/PD 2025, scheduled from April 1–5 in Vienna. During the conference, the company Annovis gave two presentations, showcasing findings from its Phase III Parkinson's disease trial and data on buntanetap in ApoE4 carriers from its Phase II/III Alzheimer's disease study. In February 2025, the FDA granted Fast Track Designation (FTD) to amlenetug for the treatment of MSA. In January 2025, Annovis Bio secured a significant milestone with the issuance of a US patent protecting its novel methods for treating and preventing acute brain and nerve injuries through buntanetap. Discover which indication is expected to grab the major alpha-synuclein inhibitors market share @ Alpha-synuclein Inhibitors Market Report Alpha-synuclein Inhibitors Market Dynamics The alpha-synuclein inhibitors market is driven by the growing prevalence of neurodegenerative disorders such as Parkinson's disease, Lewy body dementia, and multiple system atrophy, where alpha-synuclein aggregation plays a critical pathogenic role. With the global burden of Parkinson's disease expected to double by 2040, there is a pressing demand for disease-modifying therapies that can go beyond symptomatic relief. Current treatment options, such as dopaminergic drugs, primarily address motor symptoms but fail to halt disease progression. This unmet medical need is pushing pharmaceutical and biotechnology companies to focus on alpha-synuclein inhibitors, which target the underlying pathology by preventing protein misfolding, aggregation, and the subsequent neurodegenerative cascade. Significant research and development investments are shaping the competitive landscape of the alpha-synuclein inhibitors market. Several leading pharmaceutical players are actively pursuing monoclonal antibodies and small molecule inhibitors targeting alpha-synuclein. Clinical trials have advanced the understanding of the therapeutic potential of targeting alpha-synuclein, though some setbacks have been observed due to limited clinical efficacy in late-stage trials. Nonetheless, advancements in biomarker discovery and imaging technologies for early diagnosis and monitoring disease progression are expected to enhance the success rate of ongoing and future clinical programs. Market dynamics are also influenced by regulatory and reimbursement factors. Given the high cost and complexity of neurodegenerative disease drug development, regulatory agencies like the FDA and EMA are encouraging accelerated pathways and breakthrough therapy designations for promising candidates. However, high development costs, combined with stringent clinical efficacy requirements, pose challenges for new entrants and smaller biotech firms. Moreover, reimbursement policies in major markets will play a critical role in determining the commercial success of these therapies once approved. Collaborations and strategic partnerships are increasingly shaping the alpha-synuclein inhibitors landscape. Big pharmaceutical companies are entering licensing agreements, mergers, or co-development partnerships with biotech firms to expand their neurodegenerative pipelines. For instance, Roche and Prothena's collaboration on prasinezumab reflects the industry trend of leveraging external innovation to accelerate drug development. Furthermore, increasing venture capital funding and public-private initiatives are supporting the growth of innovative startups working on novel alpha-synuclein-targeting approaches, such as antisense oligonucleotides and gene therapy-based strategies. Looking ahead, the alpha-synuclein inhibitors market is poised for steady growth. The next decade is expected to witness significant milestones in the approval and commercialization of disease-modifying therapies, which could revolutionize the treatment paradigm for Parkinson's and related disorders. Alpha-synuclein Inhibitors Treatment Market Alpha-synuclein inhibitors are therapeutic agents developed to prevent the aggregation of alpha-synuclein, a protein closely linked to neurodegenerative disorders such as Parkinson's disease, Lewy body dementia, and multiple system atrophy. These inhibitors function by blocking protein misfolding, reducing toxic buildup, and promoting clearance pathways. By targeting alpha-synuclein pathology, they aim to slow the progression of these diseases, offering promising advancements in neuroprotection and symptom relief. Although no alpha-synuclein inhibitors have yet received regulatory approval, the FDA has issued a 'Letter of Support' encouraging the use of the synuclein-based biomarker, αSyn-SAA, in clinical trials for Parkinson's disease and related disorders. This recognition underscores the biomarker's potential to improve disease monitoring, streamline drug development, and refine treatment strategies. With no approved therapies in this category, several companies, including Annovis Bio, Roche/Prothena, and Lundbeck, are actively progressing their pipelines to develop innovative candidates. These initiatives aim to enhance therapeutic approaches, improve drug effectiveness, and address the significant unmet needs in neurodegenerative conditions such as Parkinson's, Lewy body dementia, and MSA. Learn more about the alpha-synuclein inhibitors @ Alpha-synuclein Inhibitors Analysis Key Emerging Alpha-synuclein Inhibitors and Companies Emerging alpha-synuclein inhibitors in the pipeline, including buntanetap (Annovis Biopharm), prasinezumab (Roche/Prothena), amlenetug (Lundbeck), and others, are showing promise for expanding treatment options. Buntanetap, formerly known as Posiphen or ANVS401, works against neurodegeneration by preventing the build-up of toxic proteins such as amyloid beta, tau, alpha-synuclein, and TDP43. This action helps boost synaptic function, improve axonal transport, and reduce neuroinflammation—key processes required to maintain healthy neurons. The accumulation of these proteins disrupts neural pathways, leading to neuronal damage and cell death, which underlie diseases like Alzheimer's and Parkinson's. By targeting these mechanisms, buntanetap aims to reverse neurodegeneration, restore brain function, and significantly enhance patients' quality of life. In March 2025, Annovis Bio participated in the AD/PD 2025 conference (April 1–5, Vienna), where it delivered two presentations highlighting data from its Phase III Parkinson's disease trial and findings on buntanetap in ApoE4 carriers from its Phase II/III Alzheimer's disease study. Earlier, in July 2024, Annovis announced results from its Phase III Parkinson's disease trial (NCT05357989). Among patients diagnosed with Parkinson's for over three years, buntanetap demonstrated significant improvements in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) scores, Parts II, III, II+III, and Total, compared with placebo and baseline. Prasinezumab, an experimental monoclonal antibody, is designed to selectively bind aggregated alpha-synuclein (α-syn) and reduce its neurotoxic effects. By targeting α-syn accumulation and its cell-to-cell spread, prasinezumab has the potential to slow disease progression. Targeting α-syn aggregates is supported by extensive research as a viable therapeutic strategy for Parkinson's disease. At the AD/PD 2025 conference, the company presented results from the Phase IIb PADOVA study. While the drug showed potential in slowing motor symptom progression, it did not achieve statistical significance in the primary analysis, and further evaluations are ongoing. Amlenetug, a human monoclonal antibody, is designed to bind all major extracellular forms of α-syn, preventing their uptake and halting aggregation seeding. Its active Fc region may promote immune-mediated clearance of α-syn/antibody complexes through microglial uptake, thereby reducing pathological deposits. Developed by Lundbeck in collaboration with Genmab A/S, amlenetug is part of ongoing efforts to develop disease-modifying therapies for neurodegenerative conditions. In February 2025, the FDA granted Fast Track Designation (FTD) for amlenetug in treating multiple system atrophy (MSA). It previously received Orphan Drug Designation (ODD) from the FDA in April 2024, SAKIGAKE designation from Japan's Ministry of Health, Labour and Welfare in March 2023, and ODD from the European Medicines Agency (EMA) in May 2021. The anticipated launch of these emerging therapies are poised to transform the alpha-synuclein inhibitors market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the alpha-synuclein inhibitors market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about alpha-synuclein inhibitors clinical trials, visit @ Alpha-synuclein Inhibitors Treatment Alpha-synuclein Inhibitors Overview Alpha-synuclein is a highly soluble and intrinsically disordered protein that accumulates in Lewy bodies and Lewy neurites, playing a key role in the development of Parkinson's disease and other synucleinopathies. While predominantly located in the brain, smaller amounts are also present in the heart, muscles, and various tissues. Within neurons, α-Syn is concentrated in presynaptic terminals, where it regulates synaptic vesicle dynamics. Studies indicate that it may restrict vesicle mobility, thereby influencing synaptic recycling and neurotransmitter release. Another view suggests that α-Syn interacts with VAMP2 (synaptobrevin) to stabilize SNARE complexes, with recent research linking these interactions to synaptic function. Moreover, α-Syn may modulate dopamine release, affecting both voluntary and involuntary motor control. Synucleinopathies are marked by the accumulation of α-Syn amyloid deposits in the brain, driving neurodegeneration. Preventing α-Syn aggregation remains challenging due to its inherently disordered structure and the complex, unpredictable nature of fibrillogenesis. Nevertheless, targeting α-Syn is considered a promising therapeutic strategy, offering potential avenues for the treatment of Parkinson's disease and related conditions. Alpha-synuclein Inhibitors Epidemiology Segmentation The alpha-synuclein inhibitors market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Cases in Selected Indications for Alpha-synuclein Inhibitors Total Eligible Patient Pool in Selected Indications for Alpha-synuclein Inhibitors Total Treated Cases in Selected Indications for Alpha-synuclein Inhibitors Alpha-synuclein Inhibitors Report Metrics Details Study Period 2020–2034 Alpha-synuclein Inhibitors Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] Key Indications Covered in the Report Parkinson's disease, Alzheimer's disease, Lewy body dementia, Multiple system atrophy, and others Key Alpha-synuclein Inhibitors Companies Annovis Biopharm, Lundbeck, Roche, Prothena, and others Key Alpha-synuclein Inhibitors Buntanetap, Amlenetug, Prasinezumab, and others Scope of the Alpha-synuclein Inhibitors Market Report Alpha-synuclein Inhibitors Therapeutic Assessment: Alpha-synuclein Inhibitors current marketed and emerging therapies Alpha-synuclein Inhibitors Market Dynamics: Conjoint Analysis of Emerging Alpha-synuclein Inhibitors Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Alpha-synuclein Inhibitors Market Access and Reimbursement Discover more about alpha-synuclein inhibitors in development @ Alpha-synuclein Inhibitors Clinical Trials Table of Contents 1 Key Insights 2 Report Introduction 3 Executive Summary 4 Key Events 5 Market Forecast Methodology 6 Alpha-synuclein Inhibitors Market Overview at a Glance in the 7MM 6.1 Market Share (%) Distribution by Indication in 2024 6.2 Market Share (%) Distribution by Indication in 2034 7 Alpha-synuclein Inhibitors: Background and Overview 7.1 Introduction 7.2 Evolution of Alpha-synuclein Inhibitors 7.3 Treatment 8 Target Patient Pool 8.1 Key Findings 8.2 Assumptions and Rationale: 7MM 8.3 Epidemiology Scenario in the 7MM 8.3.1 Total Cases in Selected Indications for Alpha-synuclein Inhibitors in the 7MM 8.3.2 Total Eligible Patient Pool in Selected Indications for Alpha-synuclein Inhibitors in the 7MM 8.3.3 Total Treated Cases in Selected Indications for Alpha-synuclein Inhibitors in the 7MM 8.4 The US 8.4.1 Total Cases in Selected Indications for Alpha-synuclein Inhibitors in the US 8.4.2 Total Eligible Patient Pool in Selected Indications for Alpha-synuclein Inhibitors in the US 8.4.3 Total Treated Cases in Selected Indications for Alpha-synuclein Inhibitors in the US 8.5 EU4 and the UK 8.5.1 Total Cases in Selected Indications for Alpha-synuclein Inhibitors in EU4 and the UK 8.5.2 Total Eligible Patient Pool in Selected Indications for Alpha-synuclein Inhibitors in EU4 and the UK 8.5.3 Total Treated Cases in Selected Indications for Alpha-synuclein Inhibitors in EU4 and the UK 8.6 Japan 8.6.1 Total Cases in Selected Indications for Alpha-synuclein Inhibitors in Japan 8.6.2 Total Eligible Patient Pool in Selected Indications for Alpha-synuclein Inhibitors in Japan 8.6.3 Total Treated Cases in Selected Indications for Alpha-synuclein Inhibitors in Japan 9 Emerging Therapies 9.1 Key Cross Competition 9.2 Buntanetap: Annovis Biopharma 9.2.1 Drug Description 9.2.2 Others Developmental Activities 9.2.3 Clinical Trials Information 9.2.4 Safety and Efficacy 9.2.5 Analyst's View 9.3 Prasinezuma: Roche/Prothena 9.4 Amlenetug: Lundbeck List of drugs to be continued in the final report… 10 Alpha-synuclein Inhibitors: the 7MM Analysis 10.1 Key Findings 10.2 Key Market Forecast Assumptions 10.2.1 Cost Assumptions and Rebates 10.2.2 Pricing Trends 10.2.3 Analogue Assessment 10.2.4 Launch Year and Therapy Uptakes 10.3 Market Outlook 10.4 Attribute Analysis 10.5 Total Market Size of Alpha-synuclein Inhibitors in the 7MM 10.6 The US Market Size 10.6.1 Total Market Size of Alpha-synuclein Inhibitors in the US 10.6.2 Market Size of Alpha-synuclein Inhibitors by Therapies in the US 10.7 EU4 and the UK Market Size 10.7.1 Total Market Size of Alpha-synuclein Inhibitors in EU4 and the UK 10.7.2 Market Size of Alpha-synuclein Inhibitors by Therapies in EU4 and the UK 10.8 Japan Market Size 10.8.1 Total Market Size of Alpha-synuclein Inhibitors in Japan 10.8.2 Market Size of Alpha-synuclein Inhibitors by Therapies in Japan 11 Unmet Needs 12 SWOT Analysis 13 KOL Views 14 Market Access and Reimbursement 14.1 The US 14.2 EU4 and the UK 14.3 Japan 15 Bibliography 16 Report Methodology Related Reports Parkinson's Disease Market Parkinson's Disease Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson's disease companies, including UCB Biopharma SRL, Novartis, Annovis Bio, Supernus Pharmaceuticals, Inc., Britannia Pharmaceutical, Pharma Two B, Mitsubishi Tanabe Pharma (NeuroDerm), AbbVie, Cerevel Therapeutics, LLC, among others. Alzheimer's Disease Market Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Alzheimer's disease companies including AB Science, Alzheon Inc., AriBio Co., Ltd., AgeneBio, Inc., Anavex Life Sciences Corp., Annovis Bio, Inc., Cerecin, BioVie, Cassava Sciences, Novo Nordisk, Eli Lilly, Neurim Pharmaceuticals, Suven Life Sciences, Bristol-Myers Squibb, Karuna Therapeutics, T3D Therapeutics, Inc., Lexeo Therapeutics, Axsome Therapeutics, Inc., Araclon Biotech S.L., Eisai Co., Ltd., TauRx Therapeutics, TrueBinding, Inc., AC Immune SA, Johnson & Johnson, Longeveron Inc., Vaccinex Inc., IGC Pharma LLC, among others. Multiple System Atrophy Market Multiple System Atrophy Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key MSA companies including H Lundbeck A/S, Brain Neurotherapy Bio, Inc., Asklepios BioPharmaceutical, Inc., Theravance Biopharma, Ono Pharmaceutical Co. Ltd, Ionis Pharmaceuticals, Inc., Biogen, Alterity Therapeutics, Teva Pharmaceutical, MODAG GmbH, among others. Lewy Body Dementia Market Lewy Body Dementia Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Lewy body dementia companies including EIP Pharma Inc., Cognition Therapeutics, Eisai Inc., Sun Pharma Advanced Research Company Limited, Georgetown University, Eli Lilly and Company, CuraSen Therapeutics, Inc., Athira Pharma, Aptinyx Inc., among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact UsShruti Thakur info@ +14699457679 Logo: View original content:
Malaysian Reserve
4 days ago
- Malaysian Reserve
Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
INDIANAPOLIS, July 25, 2025 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Verve Therapeutics, Inc. (Nasdaq: VERV). Verve is a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease. 'This acquisition unlocks the opportunity to potentially transform the treatment paradigm for millions of patients worldwide by delivering lifelong cardiovascular risk reduction with a one-and-done treatment,' said Ruth Gimeno, Lilly group vice president, Diabetes and Metabolic Research and Development. 'We are excited to welcome Verve colleagues to Lilly and work together to develop innovative genetic medicines for cardiometabolic disease.' About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit and or follow us on Facebook, Instagram, and LinkedIn. F-LLY Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements regarding Lilly's acquisition of Verve, regarding prospective benefits of the acquisition and Verve's gene editing programs for cardiovascular disease, regarding Verve's product candidates and ongoing clinical and preclinical development, and regarding Lilly's development of programs for cardiovascular disease and advancement of cardiometabolic health medicines. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements reflect current beliefs and expectations; however, these statements involve inherent risks and uncertainties, including with respect to drug research, development and commercialization, Lilly's evaluation of the accounting treatment of the acquisition and its potential impact on its financial results and financial guidance, regulatory changes and developments, the impact of global macroeconomic conditions, including trade and other global disputes and interruptions, including related to tariffs, trade protection measures, and similar restrictions, risks that the acquisition disrupts current plans and operations or adversely affect employee retention, and any legal proceedings that have been or may be instituted related to the acquisition. Actual results could differ materially due to various factors, risks and uncertainties. Among other things, there can be no guarantee that Lilly will realize the expected benefits of the acquisition, that product candidates will be approved on anticipated timelines or at all, that any products, if approved, will be commercially successful, that all or any of the contingent consideration will become payable on the terms described herein or at all, that Lilly's financial results will be consistent with its expected 2025 guidance or that Lilly can reliably predict the impact of the acquisition on its financial results or financial guidance. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the U.S. Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this press release. Refer to: Ashley Hennessey; gentry_ashley_jo@ 317-416-4363 (Media) Michael Czapar; czapar_michael_c@ 317-617-0983 (Investors)
Malaysian Reserve
4 days ago
- Malaysian Reserve
Shanton Receives Fast Track Designation from US FDA for Refractory Gout Program
SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in uncontrolled gout SINGAPORE and PRINCETON, N.J., July 25, 2025 /PRNewswire/ — Shanton Pharma, a clinical-stage biotech company developing a novel treatment for gout, today announced that FDA has designated its Investigational New Drug SAP-001 as a Fast Track product for treatment of hyperuricemia in adult patients with gout who are refractory to conventional therapy. 'We are excited about the Fast Track designation for SAP-001' says Dr. Wenfeng Miao, Shanton's CMO. 'Refractory gout is a serious condition for which there are considerable unmet medical needs, requiring the development of new treatments. We are pleased to tap into the opportunity for faster regulatory reviews provided by this designation to speed up the availability of a much-needed solution for gout patients who do not respond to or cannot tolerate Standard-of-Care treatment with conventional Urate Lowering Therapies.' FDA's decision to grant the Fast Track designation for SAP-001 was based in part on Shanton's recent efficacy and safety outcomes in a Phase 2b clinical study in which SAP-001 demonstrated the potential to meaningfully improve on currently available Urate Lowering Therapy for refractory gout patients. About Fast Track Fast Track is an FDA expedited review program which includes more frequent meetings with FDA, early and ongoing feedback from FDA, rolling review of NDA sections as they become available, and the possibility of priority review and accelerated approval. The purpose is to get important new drugs to patients earlier. About SAP-001 SAP-001 is Shanton's lead investigational compound for once-a-day oral urate-lowering therapy that targets refractory gout. SAP-001's urate lowering properties are based on a unique, First-in-Class mechanism-of-action and the product has shown Best-in-Class efficacy and safety in gout patients with hyperuricemia refractory to Standard of Care Xanthine Oxidase Inhibitor therapy in a recent Phase 2b study. About Shanton Pharma Shanton Pharma is a privately held, clinical-stage biotech founded in 2016 by experienced pharma entrepreneurs, with a research focus on unmet needs associated with hyperuricemia and gout. The company is headquartered in Singapore with research and development activities in the US, China, and Singapore. To learn more about Shanton Pharma, go to Media Contact Pieter de RidderVP of Business Developmentmedia@ Logo – View original content:
